NCT05298046View on ClinicalTrials.gov

Study of TAVO101 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 11, 2022

Primary Completion Date

June 1, 2024

Study Completion Date

September 30, 2024

Conditions
Healthy Subjects
Interventions
DRUG

Experimental: TAVO101

TAVO101 single ascending dose IV infusion.

OTHER

Other: Placebo

Placebo single ascending dose IV infusion.

Trial Locations (1)

5000

CMAX Clinical Research Pty Ltd, Adelaide

Sponsors
All Listed Sponsors
lead

Tavotek Biotherapeutics

INDUSTRY

NCT05298046 - Study of TAVO101 in Healthy Volunteers | Biotech Hunter | Biotech Hunter